Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 4, 2007, Pages 551-555

  May, S B ^a   Barroso, Paulo F ^a   Nunes, E P ^a   Barcaui, H S ^a   Almeida, M M T ^a   Costa, M D ^a   Faulhaber, J C ^a,b   Santoro Lopes, G ^a   Schechter, M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiretroviral; Brazil; HIV AIDS; Non brand name drugs; Virologic failure

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GENERIC DRUG; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT DEPARTMENT; PUBLIC HEALTH SERVICE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247197291     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000400014     Document Type: Article

References (15)

1. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679-686.
2. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach - 2003 revision. http://www.who.int/thiv/pub/prevr_care/en/ arvrevision2003en.pdf.
3. Desvarieux M, Landman R, Liautaud B, Girard PM. Antiretroviral therapy in resource-poor countries: illusions and realities. Am J Public Health 2005; 95: 1117-1122.
4. Havlir DV, Hammer SM. Patents versus patients? Antiretroviral therapy in India. N Engl J Med 2005; 353: 749-751.
5. Kumarasamy N, Vallabhaneni S, Flanigan TP, Balakrishnan P, Cecelia A, Carpenter CC, et al. Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS 2005; 19: 625-627.
6. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364: 29-34.
7. Tuboi SH, Harrison LH, Sprinz E, Albemaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005; 40: 324-328.
8. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004; 36: 967-971.
9. Braitstein P, Schachter M, Brinkhof M, Boulle A, Egger M, Dabis F. How do different types of treatment regimens affect short-term response to highly active antiretroviral treatment (HAART) among adults initiating treatment in low-income countries? [MoPe11.7C15]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment July 24-27; Rio de Janeiro; 2005.
10. Ivers LC, Kendrick D, Doucette K. Efficacy of antirestroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41: 217-224.
11. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18: 887-896.
12. Kumarasamy N, Solomon S, Chaguturu SK, Cecelia AJ, Vallabhaneni S, Flanigan TP, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005; 41: 1525-1528.
13. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
14. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-1503.
15. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-746.